Serum zinc concentration and quality of life in chronic liver diseases.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
entrez:
3
1
2020
pubmed:
3
1
2020
medline:
14
1
2020
Statut:
ppublish
Résumé
Health related quality of life (HRQOL) in chronic liver disease (CLD) patients has been attracting much attention these days because it is closely associated with clinical outcomes in CLD patients. HRQOL has become established as an important concept and target for research and practice in the fields of medicine. A critique of HRQOL research is the lack of conceptual clarity and a common definition of HRQOL. Using a clear definition of HRQOL may increase the conceptual understanding. In this study, we aimed to elucidate the association between serum zinc (Zn) level and HRQOL as assessed by the Beck Depression Inventory-2nd edition (BDI-II), Pittsburgh Sleep Quality Index Japanese version (PSQI-J) and the 36-Item Short Form Health Survey (SF-36) in CLD patients (n = 322, median age = 65 years, 121 liver cirrhosis (LC) patients (37.6%)). The median serum Zn level for all cases was 73.2 μg/dl. The median BDI-II score and PSQI-J score were 6 and 5, respectively. Patients with higher BDI-II score tended to have lower serum Zn level compared with those with lower BDI-II score. Similar tendencies were observed in patients with higher PSQI-J score. In the SF-36, physical functioning, role physical and physical component summary score significantly correlated with serum Zn level regardless of age, liver disease etiology and the LC status. While mental health and mental component summary score did not significantly correlate with serum Zn level regardless of age, liver disease etiology and the LC status. In conclusion, serum Zn level can be a useful marker for decreased HRQOL in patients with CLDs, especially for physical components.
Identifiants
pubmed: 31895823
doi: 10.1097/MD.0000000000018632
pii: 00005792-202001030-00060
pmc: PMC6946533
doi:
Substances chimiques
Zinc
J41CSQ7QDS
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e18632Références
Grüngreiff K. Zinc in liver disease. J Trace Elem Exp Med 2002;15:67–78.
Alker W, Haase H. Zinc and Sepsis. Nutrients 2018;10: pii: E976.
pii: e976
Costello LC, Franklin RB. Decreased zinc in the development and progression of malignancy: an important common relationship and potential for prevention and treatment of carcinomas. Expert Opin Ther Targets 2017;21:51–66.
Himoto T, Masaki T. Associations between zinc deficiency and metabolic abnormalities in patients with chronic liver disease. Nutrients 2018;10: pii: E88.
pii: e88
Schliess F, Gorg B, Haussinger D. RNA oxidation and zinc in hepatic encephalopathy and hyperammonemia. Metab Brain Dis 2009;24:119–34.
Grüngreiff K, Reinhold D, Wedemeyer H. The role of zinc in liver cirrhosis. Ann Hepatol 2016;15:7–16.
Vidot H, Carey S, Allman-Farinelli M, et al. Systematic review: the treatment of muscle cramps in patients with cirrhosis. Aliment Pharmacol Ther 2014;40:221–32.
Koop AH, Mousa OY, Pham LE, et al. An argument for Vitamin D, A, and zinc monitoring in cirrhosis. Ann Hepatol 2018;17:920–32.
Martínez-Peinado M, Rueda-Robles A, Nogueras-López F, et al. Serum zinc and copper concentrations and ratios in cirrhotic patients: correlation with severity index. Nutr Hosp 2018;35:627–32.
Skalny AV, Skalnaya MG, Grabeklis AR, et al. Zinc deficiency as a mediator of toxic effects of alcohol abuse. Eur J Nutr 2018;57:2313–22.
Katayama K, Saito M, Kawaguchi T, et al. Effect of zinc on liver cirrhosis with hyperammonemia: a preliminary randomized, placebo-controlled double-blind trial. Nutrition 2014;30:1409–14.
Kazunari I, Hirayuki E, Shuhei N, et al. Serum zinc value in patients with hepatitis virus-related chronic liver disease: association with the histological degree of liver fibrosis and with the severity of varices in compensated cirrhosis. J Clin Biochem Nutr 2014;55:147–52.
Dejong C, Deutz N, Soeters P. Muscle ammonia and glutamine exchange during chronic liver insufficiency in the rat. J Hepatol 1994;21:299–307.
Gao F, Gao R, Li G, et al. Health-related quality of life and survival in Chinese patients with chronic liver disease. Health Qual Life Outcomes 2013;11:131.
Li L, Yeo W. Value of quality of life analysis in liver cancer: a clinician's perspective. World J Hepatol 2017;9:867–83.
Younossi ZM, Stepanova M, Anstee QM, et al. Reduced patient-reported outcome scores associate with level of fibrosis in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2019;17:2552–60. e10.
Naseer M, Turse EP, Syed A, et al. Interventions to improve sarcopenia in cirrhosis: a systematic review. World J Clin Cases 2019;7:156–70.
Huang X, Liu X, Yu Y. Depression and chronic liver diseases: are there shared underlying mechanisms? Front Mol Neurosci 2017;10:134.
von Glischinski M, von Brachel R, Hirschfeld G. How depressed is “depressed”? A systematic review and diagnostic meta-analysis of optimal cut points for the Beck Depression Inventory revised (BDI-II). Qual Life Res 2019;28:1111–8.
Ghabril M, Jackson M, Gotur R, et al. Most individuals with advanced cirrhosis have sleep disturbances, which are associated with poor quality of life. Clin Gastroenterol Hepatol 2017;15:1271-1278.e6.
Mollayeva T, Thurairajah P, Burton K, et al. The Pittsburgh sleep quality index as a screening tool for sleep dysfunction in clinical and non-clinical samples: A systematic review and meta-analysis. Sleep Med Rev 2016;25:52–73.
Janik MK, Księżopolska A, Kostrzewa K, et al. Long-term health-related quality of life in living liver donors. Ann Transplant 2019;24:45–51.
Wu MK, Hsu LW, Huang KT, et al. Assessment of relevant factors with respect to psychosocial properties in potential living donor candidates before liver transplantation. Neuropsychiatr Dis Treat 2018;14:1999–2005.
Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression”. Arch Gen Psychiatry 1961;4:561–71.
Jay CL, Butt Z, Ladner DP, et al. A review of quality of life instruments used in liver transplantation. J Hepatol 2009;51:949–59.
Konno S, Oda N, Ochiai T, et al. Randomized, double-blind, placebo-controlled phase III trial of duloxetine monotherapy in japanese patients with chronic low back pain. Spine (Phila Pa 1976) 2016;41:1709–17.
Matsunami K, Nishida N, Kaneko N, et al. Genome-wide association study identifies ZNF354C variants associated with depression from interferon-based therapy for chronic hepatitis C. PLoS One 2016;11:e0164418.
Kawase K, Kondo K, Saito T, et al. Risk factors and clinical characteristics of the depressive state induced by pegylated interferon therapy in patients with hepatitis C virus infection: A prospective study. Psychiatry Clin Neurosci 2016;70:489–97.
Buysse DJ, Reynolds CF 3rd, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193–213.
Doi Y, Minowa M, Uchiyama M, et al. Psychometric assessment of subjective sleep quality using the Japanese version of the Pittsburgh Sleep Quality Index (PSQI-J) in psychiatric disordered and control subjects. Psychiatry Res 2000;97:165–72.
Fukuhara S, Ware JE Jr, Kosinski M, et al. Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey. J Clin Epidemiol 1998;51:1045–53.
Dyson JK, De Martin E, Dalekos GN, et al. IAIHG Consortium. Review article: unanswered clinical and research questions in autoimmune hepatitis-conclusions of the International Autoimmune Hepatitis Group Research Workshop. Aliment Pharmacol Ther 2019;49:528–36.
Ridola L, Nardelli S, Gioia S, et al. Quality of life in patients with minimal hepatic encephalopathy. World J Gastroenterol 2018;24:5446–53.
Haraldstad K, Wahl A, Andenæs R, et al. LIVSFORSK network. A systematic review of quality of life research in medicine and health sciences. Qual Life Res 2019;28:2641–50.
Staquet M, Berzon R, Osoba D, et al. Guidelines for reporting results of quality of life assessments in clinical trials. Qual Life Res 1996;5:496–502.
Moons P, Budts W, De Geest S. Critique on the conceptualization of quality of life: A review and evaluation of different conceptual approaches. Int J Nurs Stud 2006;43:891–901.
Takuma Y, Nouso K, Makino Y, et al. Clinical trial: oral zinc in hepatic encephalopathy. Aliment Pharmacol Ther 2010;32:1080–90.
Kamimura K, Sakamaki A, Kamimura H, et al. Considerations of elderly factors to manage the complication of liver cirrhosis in elderly patients. World J Gastroenterol 2019;25:1817–27.
Nishikawa H, Kimura T, Kita R, et al. Treatment for hepatocellular carcinoma in elderly patients: a literature review. J Cancer 2013;4:635–43.
Loustaud-Ratti V, Jacques J, Debette-Gratien M, et al. Hepatitis B and elders: an underestimated issue. Hepatol Res 2016;46:22–8.
Osaki Y, Nishikawa H. Treatment for hepatocellular carcinoma in Japan over the last three decades: our experience and published work review. Hepatol Res 2015;45:59–74.
Roohani N, Hurrell R, Kelishadi R, et al. Zinc and its importance for human health: an integrative review. J Res Med Sci 2013;18:144–57.